Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin.
Antimuscarinic agents, effective in relieving symptoms of overactive bladder, are associated with anticholinergic-mediated adverse events, particularly at high dosages. The outcome of a difficult-to-treat patient requiring high doses of anticholinergic therapy who was successfully treated with transdermal oxybutynin after failing oral therapies is reported.
Saltzstein
Leslie
L
Adult Bladder Control Center of Urology Associates, Grand Rapids, MI, USA.
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000369:Aged, 80 and over; D002626:Chemistry, Pharmaceutical; D003248:Constipation / Q000139:chemically induced; D005081:Exercise Therapy; D005260:Female; D006801:Humans; D008333:Mandelic Acids / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D018727:Muscarinic Antagonists / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D017773:Pelvic Floor; D012648:Self Care; D014039:Toilet Training; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D014563:Urodynamics
D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin